Drug intelligence / Profile preview

iguratimod + tocilizumab

Development stage: Preclinical
Lead developer: Eisai
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

A combination therapy consisting of iguratimod (IGU), a novel synthetic small molecule disease-modifying anti-rheumatic drug, and tocilizumab (TCZ), a recombinant humanized monoclonal antibody against the interleukin-6 receptor. This combination is primarily used as an add-on therapy for patients with rheumatoid arthritis who show inadequate response to tocilizumab monotherapy. Clinical studies have demonstrated that adding iguratimod to tocilizumab therapy significantly improves disease activity measures such as DAS28-CRP and CDAI scores in patients with insufficient response to tocilizumab alone.

Targets

IL-6R (Interleukin-6 receptor subunit alpha)

Beyond the preview

Go deeper on iguratimod + tocilizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iguratimod + tocilizumab.

Explore the full profile